department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Injectafer · pharmadog

pharmadog
drugs
Injectafer

drug

patient view →

ferric carboxymaltose

Marketedupdated 2mo ago

by American Regent Inc

Approved

community read0 votes

all catalysts(1)

phase 1 completion · 1

phase 1 completion

Actimus Biosciences Pvt Ltd — ferric carboxymaltose (Phase I Trial Completion)

ferric carboxymaltose

News(0)

no news has mentioned this drug yet

brand

Injectafer

generic

ferric carboxymaltose

indication

Iron Deficiency Anemia

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 8, 2027

185 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (24)

Feb 15, 2028method-of-use (U-3313)US 77547021.6y
Feb 15, 2028method-of-use (U-3313)US 77547021.6y
Feb 15, 2028method-of-use (U-3312)US 77547021.6y
Feb 15, 2028method-of-use (U-3312)US 77547021.6y
Feb 5, 2027compositionUS 7612109213d
Feb 5, 2027compositionUS 7612109213d
Feb 5, 2027compositionUS 7612109213d
Feb 5, 2027compositionUS 7612109213d
Jan 8, 2027method-of-use (U-3637)US 11364260185d
Jan 8, 2027method-of-use (U-3637)US 11364260185d
Jan 8, 2027method-of-use (U-3637)US 11364260185d
Jan 8, 2027method-of-use (U-3637)US 11364260185d
Jan 8, 2027method-of-use (U-3634)US 11433091185d
Jan 8, 2027method-of-use (U-3634)US 11433091185d
Jan 8, 2027method-of-use (U-3634)US 11433091185d
Jan 8, 2027method-of-use (U-3634)US 11433091185d
Jan 8, 2027method-of-use (U-3474)US 11478502185d
Jan 8, 2027method-of-use (U-3474)US 11478502185d
Jan 8, 2027method-of-use (U-3474)US 11478502185d
Jan 8, 2027method-of-use (U-3474)US 11478502185d
Jan 8, 2027method-of-use (U-3316)US 8895612185d
Jan 8, 2027method-of-use (U-3315)US 8895612185d
Jan 8, 2027method-of-use (U-3315)US 8895612185d
Jan 8, 2027method-of-use (U-3115)US 8895612185d

FDA exclusivities (4)

May 31, 2026I-915Indication (3y)
May 31, 2026I-915Indication (3y)
May 31, 2026I-915Indication (3y)
May 31, 2026I-915Indication (3y)

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 50m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 2

drugiron1 co-mentions · 1 sources
companyActimus Biosciences Pvt Ltd1 co-mentions · 1 sources

Trials studying ferric carboxymaltose

phase4Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndromerecruitingn=538
phase4IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approachesrecruitingn=250
phase4Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Ironcompletedn=1,025
phase1Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participantscompletedn=84
phase2Intravenous Iron Metabolism in Restless Legs Syndromecompletedn=12
phase2Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemiaterminatedn=70
N/AHypoferritinemia Without Anemia Among Reproductive Age Femalesactive not recruitingn=1,331
phase3Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantationcompletedn=148

more trials →